Stifel Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis maintains a Buy rating on Biomarin Pharmaceutical and raises the price target from $112 to $115.
August 21, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Paul Matteis has reiterated a Buy rating for Biomarin Pharmaceutical and increased the price target from $112 to $115, indicating confidence in the company's future performance.
The increase in price target from $112 to $115 by Stifel suggests a positive outlook on Biomarin's future performance. The Buy rating indicates that the analyst expects the stock to outperform, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100